期刊文献+

安体舒通联合依那普利对扩张型心肌病心功能及心肌纤维化的疗效观察

原文传递
导出
摘要 目的评价醛固酮拮抗剂安体舒通(Aldosterone)联合血管紧张素转换酶抑制剂依那普利(Enalapril)对原发性扩张型心肌病(DCM)改善心功能及逆转心肌纤维化的作用。方法83例DCM心力衰竭患者随机分为对照组和治疗组,对照组为依那普利加基础用药,治疗组为对照组用药加上安体舒通。治疗6个月后复查心脏超声指标和血清心肌纤维化指标。结果治疗后两组心脏超声指标改善,心肌纤维化指标下降;且治疗组与对照组比较,改善明显,治疗组与对照组比较差异有统计学意义(P〈0.01)。结论安体舒通联合依那普利能明显改善心功能及逆转DCM心肌纤维化。
出处 《中国医师杂志》 CAS 2009年第11期1571-1572,共2页 Journal of Chinese Physician
  • 相关文献

参考文献3

二级参考文献33

  • 1[10]Beggah AT,Escoubet B,Puttini S,et al.From the cover:reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes.Proc Nat Acad Sci U S A 2002;99:7160-5.
  • 2[11]Sabbah HN,Sharov VG,Lesch M,et al.Progression of heart failure:a role for interstitial fibrosis.Mol Cell Biochem 1995;147:29-34.
  • 3[12]Zannad F,Alla F,Dousset B,et al.Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure:insights from the randomized aldactone evaluation study(RALES).Circulation 2000;102:2700-6.
  • 4[13]Zannad F,Dousset B,Alla F.Treatment of congestive heart failure:interfering the aldosterone-cardiac extracellular matrix relationship.Hypertension 2001;38:1227-32.
  • 5[14]Querejeta R,Lopez B,Gonzalez A,et al.Increased collagen type Ⅰ synthesis in patients with heart failure of hypertensive origin:relation to myocardial fibrosis.Circulation 2004;110:1263-8.
  • 6[1]Banff C,Cavalca V,Veglia F,et al.Neurohormonal activation is associated with increased levels of plasma matrix metalloproteinase-2 in human heart failure.Eur Heart J 2005;26:481-8.
  • 7[2]Reinhardt D,Sigusch HH,Hensse J,et al.Cardiac remodelling in end stage heart failure:upregulation of matrix metalloproteinase(MMP)irrespective of the underlying disease,and evidence for a direct inhibitory effect of ACE inhibitors on MMP.Heart2002;88:525-30.
  • 8[3]Yamazaki T,Lee JD,Shimizu H,et al.Circulating matrix metalloproteinase-2 is elevated in patients with congestive heart failure.Eur J Heart Fail 2004;6:41-5.
  • 9[4]Wilson EM,Gunasinghe HR,Coker ML,et al.Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure.J Card Fail 2002;8:390-8.
  • 10[5]Spinale FG,Coker ML,Heung LJ,et al.A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure.Circulation 2000;102:1944-9.

共引文献71

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部